Insider buying · SEC Form 4

Insider Buying — Jun 12, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

3insider buys
$29.5Mbought in total
3companies
0by CEOs, CFOs and other chiefs
HOODlargest: $20.2M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
HOODRobinhood Markets, Inc.Meyer MalkaDirector$20.2M250,000$80.74AddedJun 12, 2026
Form 4 ↗
Weighted avg $80.74/share; third open-market tranche in 2 weeks by Ribbit Capital-affiliated entities, bringing cumulative total to ~$55M. Current price $92.23 (+14.2% vs buy price). Malka is HOOD founding VC backer and board director since 2022.
STEPStepStone Group Inc.Michael I. McCabeHead of Strategy / Director$5.02M120,000$41.85AddedJun 11, 2026
Form 4 ↗
Weighted avg $41.85/share (range $41.25–$42.62); bought ~10 business days after Q4 FY2026 earnings (8-K filed May 29). Current price $42.52 (+1.6% vs buy). Boosts direct stake 38% to 433,178 shares.
ARTVArtiva Biotherapeutics, Inc.Peter Kolchinsky / RA Capital Management L.P.Director / 10% Owner$4.34M548,580$7.91AddedJun 11, 2026
Form 4 ↗
Weighted avg $7.91/share (range $7.605–$8.00); final leg of 3-day cluster buy (June 9–11) totalling ~$7.65M. RA Capital holds 33.7% stake. Current price $8.00 (+1.1% vs buy). NK-cell therapy biotech.

AIThe day in insider buying

SEC Form 4 Insider Scan — June 12, 2026

Scanned the last 24 hours of EDGAR Form 4 filings. 3 qualifying buys (≥ $250K, transaction type P) totalling $29.5M.

Headline filings

  • HOOD — Meyer Malka (Director) bought 250,000 shares ≈ $20.2M at $80.74 avg; now $92.23 (+14.2% since buy). (filing) Third consecutive open-market tranche for Robinhood's founding VC director, bringing Ribbit-affiliated total to ~$55M in two weeks.
  • STEP — Michael I. McCabe (Head of Strategy / Director) bought 120,000 shares ≈ $5.0M at $41.85 avg (range $41.25–$42.62); now $42.52 (+1.6% since buy). (filing) Boosts direct stake to 433,178 shares (+38%), filed same-day as transaction, post-StepStone Q4 FY2026 earnings.
  • ARTV — Peter Kolchinsky / RA Capital Management (Director / 10% Owner) bought 548,580 shares ≈ $4.3M at $7.91 avg (range $7.605–$8.00); now $8.00 (+1.1% since buy). (filing) Final leg of a 3-day cluster buy (June 9–11) totalling ~$7.65M; RA Capital controls a 33.7% stake in this NK-cell therapy biotech.

Notes

Themes: Fintech conviction (HOOD) and alternative asset management (STEP) dominate today's scan, with a concentrated biotech fund buy (ARTV) rounding out the list.

HOOD — Ribbit Capital conviction. Meyer Malka has now deployed ~$55M into HOOD across three open-market tranches in under two weeks. HOOD is already +14.2% above his latest buy price, yet he kept accumulating at each step. Malka has been on the board since 2022 and is Robinhood's original institutional backer — this scale of insider accumulation is a strong signal.

STEP — Post-earnings non-blackout buy. StepStone reported Q4 FY2026 results on May 29; McCabe's $5M purchase on June 11 — well past the typical quiet period — reads as a deliberate, fully-informed open-market buy. Prices ranged from $41.25 to $42.62, suggesting McCabe legged in across the session.

ARTV — 3-day cluster from lead investor. RA Capital (Peter Kolchinsky & Rajeev Shah) bought on June 9, 10, and 11, totalling ~$7.65M across the three-day window. Artiva Biotherapeutics is developing off-the-shelf NK cell therapies; persistent multi-day accumulation by the 33.7% anchor investor suggests conviction in near-term data or catalysts.

Most-bought stocks, last 30 days

  • RSG $201M · 2 buys, 2 insidersRepublic Services, Inc.
  • HOOD $85.5M · 5 buysRobinhood Markets, Inc.
  • WGS $78.1M · 4 buys, 2 insidersGeneDx Holdings Corp.
  • ALKT $65.9M · 2 buys, 2 insidersAlkami Technology, Inc.
  • FBIN $31.3M · 4 buysFortune Brands Innovations, Inc.
  • BH $28.2M · 4 buys, 4 insidersBiglari Holdings Inc.
  • NCLH $27.5M · 2 buys, 2 insidersNorwegian Cruise Line Holdings Ltd.
  • NSP $23.8M · 3 buysInsperity Inc.
  • TXO $18.4M · 3 buysTXO Partners, L.P.
  • FOUR $15.9M · 1 buyShift4 Payments, Inc.
  • PAR $10.5M · 1 buyPAR Technology Corp.
  • WCN $7.61M · 1 buyWaste Connections, Inc.
  • MNSO $6.90M · 1 buyMINISO Group Holding Limited
  • NOMD $6.63M · 1 buyNomad Foods Limited
  • ONON $6.59M · 3 buys, 3 insidersOn Holding AG
  • MRP $6.42M · 1 buyMillrose Properties, Inc.
  • TKO $6.00M · 3 buys, 2 insidersTKO Group Holdings, Inc.
  • UA $5.87M · 1 buyUnder Armour, Inc.
  • LODE $5.78M · 4 buys, 4 insidersComstock Inc.
  • SLMT $5.71M · 1 buySolmate Infrastructure Public Ltd (f/k/a Brera Holdings PLC)

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.